Neoplasms

Gland and Hormone Related Diseases

All Conditions

Thyroid Neoplasms

Thyroid Diseases

Hypothyroidism

Goiter

Endocrine System Diseases

Central Nervous System Depressants

All Drugs and Chemicals

Other Dietary Supplements

Benzocaine

Tannic Acid

Levothyroxine (LT4) and placebo (a look-alike inactive substance, a "sugar pill") Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in "AM" and "PM" color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation.

Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in "AM" and "PM" color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3.

Levothyroxine

Liothyronine sodium tablets for oral use treatment of hypothyroidism

Liothyronine

inert sugar tablets for oral use blinding for treatment of hypothyroidism

Placebo

Angeliki M Stamatouli, MD

The purpose of this research study is to measure the changes in energy metabolism (how the body burns energy), cardiovascular function (heart function), and lipid metabolism (cholesterol break down and building) before and after thyroidectomy (surgical removal of thyroid gland) in response to two approved therapies for hypothyroidism: levothyroxine (LT4) or Liothyronine/levothyroxine (LT3/LT4) combination therapy.

In this study, Levothyroxine (LT4) and placebo (a look-alike inactive substance, a "sugar pill") will be compared to Liothyronine/ Levothyroxine (LT3/LT4) combination therapy.

Levothyroxine LT4 and Liothyronine (LT3) are drugs approved by the U. S. Food and Drug Administration (FDA).

All participants will be required follow VCU Health COVID-19 standard of Care screening procedures.

This study requires approximately five study visits The five-study visits required will be a Screening Visit (outpatient), one Baseline Visit, (inpatient) one Six Week Visit, (outpatient), one Three Month Visit and one Six Month Visit (both inpatient). A COVID-19 test will be done 48 hours (2 days) before each of the three-inpatient visit, Baseline Visit, Three Month and Six Month Visit.

Participants will be asked to:

1. Give permission for the researchers to collect information about their medical history from participants and their medical records five times during the study visits and for 5 years after the study visits.
2. Have a Physical exam done 5 times
3. 24-hour energy expenditure recording in the Whole room indirect calorimeter studies 3 times (inpatient overnight stays: Baseline, Three months, and Six months visits)
4. Study drug will be dispensed three times
5. Have study drug dose adjustments two times
6. Genomic blood draw for DNA one time
7. Have blood drawn five times
8. Have an DXA Scan two times
9. Have an Echocardiogram three times
10. Complete questionnaire three times
11. Have Accelerometers sensors laced 3 times (inpatient overnight stays: Baseline, Three months, and Six months visits)
12. ClearSight (blood pressure monitoring) procedure three times
13. Be randomized to take either Levothyroxine LT4 + placebo group or LevothyroxineLT3/Liothyronine LT4 group from baseline through 6 months

Participation in this study will last up to 6 months after surgery. Approximately 30 total individuals will participate in this study

Energy Metabolism in Thyroidectomized Patients

ThyPRO-39, a thyroid specific quality of life instrument

Weight will be measured in kilograms using a stadiometer

24-hour EE will be measured using the whole room indirect calorimeter (WRIC) technique

Cholesterol will be measured using a standard lipid panel.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Virginia Commonwealth University

Digestive System Diseases

Ear, Nose, and Throat Diseases

Mouth and Tooth Diseases

Thyroid Nodule

Thyroiditis

Deglutition Disorders

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Esophageal Diseases

Gastrointestinal Diseases

Pharyngeal Diseases

Otorhinolaryngologic Diseases

Patients s/p post-thyroidectomy without complication

\*will NOT be enrolled to standard dysphagia-rehabilitation treatment

Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.

\*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week.

Patients s/p post-thyroidectomy dysphagia only.

\*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week.

DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.

Total thyroidectomy

Ethem UNAL, MD, PhD, USMLE, IFSO & Board CSS

Sema YUKSEKDAG, MD

Ethem UNAL, MD, PhD, ECFMG, IFSO & Board CSS

Kadir M YILDIRAK, MD

The most common and feared complications of total thyroidectomy are vocal cord paralyses and hypocalcemia. However, post-thyroidectomy dysphagia is not uncommon and has important consequences on the quality of life (QoL). It should be taken seriously by all clinicians.

Dysphagia is a possible complication that can be observed in patients undergoing thyroidectomy, and can be related to superior and inferior laryngeal nerves dysfunction, but it usually appears after an uncomplicated surgical procedure. Aerodigestive symptoms, such as discomfort, tightness, lump, foreign body, difficulty or pain during swallowin, can also present before operation. If it appears or aggrevates after surgery, laryngeal nerve damage (superior laryngeal nerve - SLN, or inferior laryngeal nerve - recurrent, RLN), tracheo-malacia and postoperative fibrotic changes should be interrogated. However, in most of the cases, an anatomic and/or physiologic defect in the oro-pharngeal region is not easy to be detected. Therefore, a subjective feeling of dysphagia is more common.

Dysphagia has important consequences on the QoL in postoperative period, and should be addressed by the primary surgeon/clinician, regardless of whether it is objective or subjective.

The goal of the present study is to better understand the incidence of postoperative dysphagia symptoms among patients who have undergone total thyroidectomy for benign or malign thyroid disease. Besides, all possible risk factors (pre-intra-post-operative) are also going to be evaluated in detail, and the efficacy of a 6-week dysphagia-rehabilitation programme will also be employed and results will be shared.

Dysphagia among patients who have undergone total hyroidectomy for benign/malign thyroid disease. The preoperative factors (demographics; co-morbidities such as diabetes, multiple sclerosis, Parkinson's; body mass index; routine ear-nose-throat-ENT consultation), operative factors (over-manipulation, injury to larynx/neural plexus, easy/hard tracheal intubation, closure of strap muscles/stay open) and postoperative evaluation 1-No dysphagia, 2-Dysphagia with at least one other complication (nerve injury, hypocalcemia), 3-Dysphagia without any other surgical complications; ENT\&neurology consultations, survey.

THE STUDY IS OPEN TO ALL SURGICAL CLINICS OVER THE WORLD EAGER TO JOIN; EXCEL WITH FORMS TO BE FILLED ARE AVAILABLE, please contact the principle/co-investigators by phone/e-mail.

Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT

Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT)

Excel documents including data (patient ID and protocol # will be shaded) available upon request

Subjective survey form to be filled- a self-evaluation questionnaire-to evaluate 'Change from baseline postoperative (po) day 1-3 to week 2, po week 6, po week 16, po week 24, po week 36 and po week 48 (last). A new form will be filled in for each outpatient clinic control.

assessing common dysphagia symptoms- includes 6 items scored within a range of 0 (without swallowing alterations) to 24 (maximum swallowing dysfunction).

Objective survey form to be filled- a clinician-oriented questionnaire assessing the swallowing function objectively, from stage I (normal function) to stage V (no oral intake). To evaluate change in dysphagia from baseline po day 1-3 to .po week 2, po week 6, po week 16, po week 24, po week 36 and po week 48 (last). A new form will be filled in for each outpatient clinic control.

Flexible fiberoptic laryngoscopy (any anatomic explanation for dysphagia? YES or NO? To evaluate change in dysphagia from baseline at postoperative (po) week 6 to po week 24, po week 48 (last).

EMG-electromyography test (any anatomic and/or physiologic dysfunction? YES or NO? To evaluate change in dysphagia from baseline at postoperative (po) week 6 to po week 24, po week 48 (last).

Any anatomic defect? EGD will be performed once at Postoperative (po) week 6.

6-week treatment, starting from po week 6, for all patients with dysphagia- ending at po week 12. Any improvement after 6-week treatment? evaluate at po week 12 and please answer: Any improvent in dysphagia symptom? -YES or NO?

Umraniye Education and Research Hospital

Associated Professor of General Surgery and Surgical Oncology

Eye Diseases

Immune System Diseases

Rare Diseases

Graves Disease

Hypoparathyroidism

Exophthalmos

Orbital Diseases

Hyperthyroidism

Autoimmune Diseases

Parathyroid Hormone

ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.

Indocyanine Green

Jesse Pasternak, MD, MPHc

This study aims to develop a standardized universal imaging protocol for ICG-guided fluorescent total thyroidectomy, including quantitative evaluations of the fluorescent signal. Therefore, patients will undergo thyroid surgery (total thyroidectomy) with the use of ICG fluorescence.

Background Thyroid surgery volume continues to increase worldwide over the past few decades. During a total thyroidectomy (TTx), the ultimate goal is to remove all thyroid tissue, whereas damage to adjacent tissue is prevented. However, iatrogenic hypoparathyroidism, as a result of surgical removal or damage to the parathyroid glands, occurs in approximately 30% of the cases. In 2016 near-infrared fluorescence guided surgery with indocyanine green (ICG) was proposed for visualizing viability and blood supply of parathyroid glands during TTx. ICG can visualize tissue perfusion, since it becomes completely and permanently fixed to plasma proteins once in the bloodstream, and circulates in the intravascular compartment only. However, one of the limitations of ICG imaging is the subjectivity of the interpretation of fluorescence, which makes the assessment of images inconsistent among studies. There is a clear need for standardization of the evaluation of the perfusion with ICG, since visual evaluation of the fluorescent signal of ICG is not sufficient to reliably predict the perfusion of parathyroid glands.

Main research question To develop a standardized universal imaging protocol for ICG-guided fluorescent total thyroidectomy including quantitative evaluations of the fluorescent signal.

Design This will be a proof-of-concept , prospective cohort study of patients undergoing a total thyroidectomy with ICG-guided fluorescent surgery to evaluate tissue perfusion The main study endpoint is quantification of the fluorescent signal of ICG. Secondary outcomes are data from surgery, postoperative lab values (including calcium, PTH, albumin) and postoperative medication use.

Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment

Quantification of the fluorescent signal of ICG

Vascularization appearance of parathyroid gland intraoperatively (1= surgeon thinks parathyroid gland is well vascularized, 2 = surgeons thinks parathyroid gland is devascularized)

Postoperative albumin-corrected calcium concentration in blood

Rate of prescribed postoperative calcium medication

Rate of prescribed postoperative vitamin D medication

University Health Network, Toronto

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Patients set for total thyroidectomy incl. functional total thyroidectomies.

Both 2D and 3D ultrasound is being used. 3D using optical tracking.

BK 5000 Ultrasound Machine

Klara Bay Rask

Tobias Todsen, MD, PhD, Associate Professor

Tobias Todsen, MD, PhD, associate professor

The purpose of this clinical trial is to investigate the accuracy of applying three-dimensional ultrasound on thyroid gland patients when determining a gland volume.

The method will be compared to conventional b-mode ultrasound where three axis measurements (length, width, and depth) are evaluated in the ellipsoid model.

The three dimensional (3D) method is utilizing optical tracking connected to the ultrasound image to form cross-sectional imaging. Patients enrolled in the study are set for complete thyroidectomies enabling a true volume of the gland by water displacement after excision.

The aim is to find if this 3D method is more accurate in volume estimation than the ellipsoid model.

Three-dimensional Ultrasonography Thyroid Volume Measurement.

Three-dimensional Ultrasonography: Accuracy in Thyroid Volume Measurement.

Obtaining thyroid volume with 2D ultrasound (length x Width x depth\*(Pi/6)) and 3D ultrasound with optical tracking and comparing the respective methods with a reference volume. Water displacement being gold standard for reference volume.

Looking af the change in volume invivo vs exvivo w. 2D and 3D ultrasound

Variation in volume estimation when delineating ultrasound images.

Rigshospitalet, Denmark

Stud.Med.

Thyroid Cancer, Papillary

Adenocarcinoma

Adenocarcinoma, Papillary

Carcinoma

Papillary Thyroid Carcinoma

Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.

Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.

This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.

Bipolar vessel sealing and cutting device

Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.

Conventional thyroidectomy

Miguel F Herrera, MD PhD

David Velázquez, MD MSc PhD

Erivelto Volpi, MD

Eriverto M Volpi, MD

Miguel F Herrera Hernández, MD PhD

Miguel F Herrrera, MD PhD

Bipolar sealing and cutting devices such as EnSeal® G2 Tissue Sealer are surgical instruments that use electrical powered diathermic energy to seal and transect tissue. These devices have shown high efficiency in a wide variety of open and laparoscopic general and gynecological surgical procedures.

The surgical performance of the EnSeal® has shown to be comparable to that of ultrasonic cutting devices in several studies. However, the efficacy of this instrument and in particular of new instruments such as the EnSeal® G2 Tissue Sealer has not been evaluated in thyroid surgery.

Our primary aim is to verify whether the EnSeal® performance is superior to the standard surgical technique for thyroidectomy in a randomized clinical trial on 2 different institutions.

Background Bipolar sealing and cutting devices such as EnSeal® G2 Tissue Sealer are surgical instruments that use electrical powered diathermic energy to seal and transect tissue. These devices have shown high efficiency in a wide variety of open and laparoscopic general and gynecological surgical procedures.

The surgical performance of the EnSeal® has shown to be comparable to that of ultrasonic cutting devices in several studies. However, the efficacy of this instrument and in particular of new instruments such as the EnSeal® G2 Tissue Sealer has not been evaluated in thyroid surgery.

Primary Aim To verify whether the EnSeal® performance is superior to the standard surgical technique for thyroidectomy in a randomized clinical trial on 2 different institutions

Patients and Methods A total of 160 patients will be included in the study. They will be divided into two groups of 80 subjects. Patients will undergo thyroidectomy in each of the two institutions: The National Institute of Medical Sciences and Nutrition in Mexico City and the Clinical Hospital in Sao Paolo Brazil. Surgical indication for thyroidectomy will comprise benign or malign diseases.

Design A balanced randomized clinical trial design for assessing superiority in 2 institutions. Patients with benign or malign thyroid disease will be balanced a priori within the 2 groups of the study.

Sample Size Calculation The estimated number of cases was calculated based on potential differences in surgical time, which is the main outcome variable with the smallest difference to detect. Sample size was calculated assuming a hypothetical mean difference of 15 minutes with an 80% of statistical power, 95% of confidence, with a 5% of alpha error (Type I error) in a two-tied distribution hypothesis. Based on these assumptions a sample size of at least 75 subjects per group (arm) is necessary.

Institutional Review Board Evaluation The protocol will be submitted for evaluation to the Institutional Review Board of each institution and will have to be approved before enrolling the first patient. This protocol follows all institutional, governmental policies and medical regulations for clinical research in human beings.

Informed Consent and Ethical Considerations All patients will receive complete information about this protocol. After a brief explanation those who accept to be enrolled will need to sign an informed consent before surgery. It is necessary that two independent witness may sign too the informed consent. All included patients will be des-identified for keeping as anonymous all the records. A special registry number will be allocated for every included subject. All potential harms and risks will be minimized for maximize the benefits. This protocol will adhere to the respect of the human dignity, privacy and autonomy.

Trial Registry The trial will be registered in ClinicalTrials.gov before enrolling the first patient.

Randomization Each group of 80 patients will be divided into 2 subgroups, one with preoperative diagnosis of benign disease and other with preoperative diagnosis of papillary thyroid carcinoma. Four sets of 42 envelopes will be prepared for randomization. All four groups (one with a benign and the other with a malignant thyroid condition) will be independently randomized in both institutions at the time of induction of the anesthesia. In a total of 80 patients, the EnSeal® G2 Tissue Sealer will be used for thyroid resection once the sub-platysmal flaps have been developed and in the opposite group, the operation will be performed using the standard tie \& suture technique by two experts.

Outcome Variables The primary outcomes will be operative time (minutes), blood loss (milliliters), loss of signal in laryngeal nerve monitoring, number of ligatures, pain intensity (score) and surgical complications (such as bleeding, hematoma, hypoparathyroidism, superior laryngeal nerve injury and recurrent laryngeal nerve palsy.

Operational Definitions

i. Operative Time Measured in minutes, starting at skin incision and ending with last closing suture of skin. Differences will be assessed using the t-student test.

ii. Blood Loss Measured in cc. Will be evaluated by weighting soaking sponges and collected blood through the aspiration cannula. Differences will be evaluated using the t-student test

iii. Loss of signal during continuous recurrent laryngeal nerve monitoring The number and time of loss or electromyography signaling of the recurrent laryngeal nerve will be recorded using continuous intraoperative neuro-monitoring and will be analyzed using the Fisher´s exact and the t-student tests

iv. Number of Ligatures: The number of ligatures placed on blood vessels will be recorded. Differences will be analyzed by the Fisher´s exact test or the Chi-squared test.

v. Pain Intensity All patients will receive a standard dose of pain medications. Pain will be assessed 12 and 24hs after surgery using a Visual Analogue Scale and pain medication dosing will be recorded. Differences will be analyzed using the t-test.

vi. Hypoparathyroidism Serum calcium, phosphorus, albumin and intact parathyroid hormone will be measured in every patient, 24 hours after surgery. Patients with a corrected calcium ≥7.5 mg/dl and no symptoms of hypocalcemia will receive no calcium supplements and no further blood tests will be obtained. In patients with symptoms (tingling trembling, parenthesis, tetanic, and cardiac manifestations) and/or corrected calcium \<7.5 mg/dl. Ca supplements will be administered and calcium / phosphorus / albumin will be measured every 2 weeks until supplements have been weaned. In the case that hypocalcemia persisted for 3 months, calcium/ phosphorus / albumin will be measured monthly up to 6 months. Transient hypoparathyroidism will be considered if hypocalcemia recovers in less than 6 months and the diagnosis of permanent hypoparathyroidism will be established if hypocalcemia persists for more than 6 months. Differences will be analyzed using the Fisher´s exact test

vii. Recurrent Laryngeal Nerve Injury All patients will undergo preoperative and postoperative laryngoscopy the day after surgery. At the end of the operation, response of will be assessed by direct stimulation of the vagus nerve and the recurrent laryngeal nerve. Acoustic response and electrical amplitude will be recorded. In the absence of vocal cord abnormalities in the postoperative laryngoscopy, no further evaluations will be performed. If vocal cord paralysis or paresis were found in the postoperative laryngoscopy, patients will enter a voice rehabilitation program and subsequent laryngoscopies will be performed 2 weeks, 3 months and 6 months after surgery until recovery. Transient recurrent laryngeal nerve paralysis or paresis will be considered if vocal cord movement recovers in less than 6 months and the diagnosis of permanent vocal cord paralysis will be established if vocal cord abnormalities persist for more than 6 months. Differences will be analyzed using the Fisher´s exact test.

Data Collection and Analysis All the data obtained from the clinical files, laboratory exams and registers from the neuro-monitoring will be saved in an Excel sheet in a numerical range. All records and databases will be kept anonymous. Correspondence including private or personal data will be avoided. Statistical analysis will be performed with a commercially available software. Variable representation will be made by means of excel, SPSS or numbers.

All included variables will be analyzed based on their own scaling. Variable distribution will be tested before any statistical inference. Non-parametric analysis will be used in the case of a non-normal distribution. Any p value ≤5% or 0.05 (type I error) will be considered as statistically significant for a two-tied hypothesis.

Publication and Authorship Considerations Any data or result obtained from this study will be planed and discussed by the two principal investigators. Authorship inclusion will be based on the Vancouver Convention and the Friedman guidelines. An author must be qualified when he/she has participated on the conception and design of the study, acquisition of data, analysis and interpretation of the data.

Any partial or total publication or public presentation of the data of this protocol will require a previous authorization from the principal investigators.

Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy

Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial

The primary outcomes will be operative time (minutes), blood loss (milliliters), transient and permanent hypoparathyroidism (calcium and PTH levels), loss of signal in laryngeal nerve monitoring, number of ligatures and pain intensity (EVA score).

The secondary outcome will determine if surgical complications (such as bleeding, hematoma, hypoparathyroidism, superior laryngeal nerve (SLN) injury and recurrent laryngeal nerve (RLN) palsy) are equivalent in both groups.

University of Sao Paulo

Ethicon Endo-Surgery

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Bone Density Conservation Agents

Hormones

Calcium

Calcium, Dietary

Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue

The purpose of this study is to evaluate safety and effectiveness of normal parathyroid tissue reimplantation in forearm subcutaneous tissue in case of accidental removal of parathyroid gland during thyroid surgery.

Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function

Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function

The primary outcome will be the assessment of reimplanted parathyroid function, evaluated by intact Parathormone (iPTH) measurement by separate blood samples (left and right arm) at 7 days, 1 month and 3 months after surgery. Ratio of 1.5 between the iPTH levels in the arm receiving graft and the opposite arm will be predictive of graft functionality

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Energy Metabolism in Thyroidectomized Patients	NCT04782856	Thyroid Goiter Hypothyroidism Thyroid Cancer	Levothyroxine Liothyronine Placebo	18 Years - 89 Years	Virginia Commonwealth University
Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT	NCT04410601	Dysphagia, Esop... Dysphagia, Oral... Dysphagia Comes... Thyroiditis Thyroid Cancer Thyroid Neoplas... Thyroid Goiter Thyroid Nodule ...	Total thyroidec...	17 Years -	Umraniye Education and Research Hospital
Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment	NCT03969108	Thyroid Cancer Thyroid Goiter Graves Disease	Indocyanine Gre...	18 Years -	University Health Network, Toronto
Three-dimensional Ultrasonography Thyroid Volume Measurement.	NCT05510609	Thyroid Thyroid Cancer Thyroid Disease... Graves Disease Thyroid Goiter Thyroid Adenoma	BK 5000 Ultraso...	18 Years - 110 Years	Rigshospitalet, Denmark
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy	NCT02140476	Thyroid Goiter Papillary Thyro...	Bipolar vessel ... Conventional th...	18 Years - 65 Years	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function	NCT02194920	Thyroid Goiter Thyroid Carcino... Multinodular Go... Graves Diseases	Thyroidectomy a...	-	University of Roma La Sapienza
Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT	NCT04410601	Dysphagia, Esop... Dysphagia, Oral... Dysphagia Comes... Thyroiditis Thyroid Cancer Thyroid Neoplas... Thyroid Goiter Thyroid Nodule ...	Total thyroidec...	17 Years -	Umraniye Education and Research Hospital

Spots Global Cancer Trial Database for thyroid goiter